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SUMMARY
Objective: To evaluate treatment responses in benign familial neonatal epilepsy
(BFNE).
Methods: We recruited patients with BFNE through a multicenter international col-
laboration and reviewed electroclinical and genetic details, and treatment response.
All patients were tested at minimum for mutations/deletions in the KCNQ2, KCNQ3,
and SCN2A genes.
Results: Nineteen patients were included in this study. A family history of neonatal
seizures was positive in 16 patients, and one additional patient had a family history
of infantile seizures. Mutations or deletions of KCNQ2 were found in 14, and of
KCNQ3 in 2, of the 19 patients. In all patients, seizures began at 2–5 days of life
and occurred multiple times per day. Four patients developed status epilepticus.
Seizures were focal, alternating between hemispheres, and characterized by asym-
metric tonic posturing associated with apnea and desaturation, followed by unilat-
eral or bilateral asynchronous clonic jerking. Twelve of 19 patients were treated
with multiple medications prior to seizure cessation. Seventeen of (88%) 19
patients were seizure-free within hours of receiving oral carbamazepine (CBZ) or
oxcarbazepine (OXC). Earlier initiation of CBZ was associated with shorter hospi-
talization (p < 0.01). No side effects of CBZ were reported. All patients had nor-
mal development and remain seizure-free at a mean follow-up period of 7.8 years
(6 months–16 years).
Significance: This study provides evidence that CBZ is safe and rapidly effective in neo-
nates with BFNE, even in status epilepticus. We propose that CBZ should be the drug
of choice in benign familial neonatal seizures.
KEYWORDS: Benign familial neonatal epilepsy, Neonatal seizures, KCNQ2, KCNQ3,
Carbamazepine, Oxcarbazepine.
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Key Points
• BFNE presents with recurrent clusters of seizures or
status epilepticus in the first days of life leading to pro-
longed hospitalization
• Seizures are focal and characterized by asymmetric
tonic component alternating laterality, associated with
apnea, and sometimes followed by asynchronous clo-
nic jerking
• Seizures promptly respond to low-dose oral carba-
mazepine even in the setting of status epilepticus
• Early diagnosis and treatment with oral carba-
mazepine is associated with dramatically shortened
hospitalization
Benign familial neonatal epilepsy (BFNE) is a rare auto-
somal-dominant condition with incomplete penetrance,
characterized by brief recurrent seizures beginning in the
first days of life. BFNE is associated in >80% of patients
with mutation in KCNQ2 or KCNQ3, which encode hetero-
mers of a voltage-gated ion channel responsible for a sub-
threshold potassium current important in limiting neuronal
excitability.1 BFNE is termed “benign” to reflect that, in
most affected individuals, seizures are limited to the first
year of life and neurologic development is normal. Never-
theless, seizures may be difficult to control in the neonatal
period, and patients are often treated with loading doses of
intravenous antiepileptic drugs (AEDs), such as phenobar-
bital and benzodiazepines, which may necessitate cardiores-
piratory support and lead to prolonged, un-necessary
hospitalizations.2 In addition, up to 25% of patients with
BFNE develop epilepsy later in life, and this risk has been
shown to correlate with the number of seizures in the neona-
tal period, potentially elevating the importance of early sei-
zure control for outcome.3
Herein we present retrospective data on the response to
AEDs in the neonatal period in a multicenter international
cohort of patients with BFNE.
Methods
Patients diagnosed with BFNE were identified through an
international collaboration involving four centers. Clinical
information was obtained directly from the referring physi-
cians. Electroclinical data were obtained from original
video–electroencephalography (EEG) recordings. Status
epilepticus (SE) was defined as recurrent seizures for >50%
of 1–3 h of recording time.4
A pair of sisters, patients 10 and 11, have been reported
previously.5 Mutations and deletions were identified using
GeneDx commercial arrays and Sanger sequencing as
described previously.5,6 Variants were queried against
ExAC and 1000 Genome databases, and sorts intolerant
from tolerant (SIFT) and Polyphen-2 software were used to
determine in silico likelihood of pathogenicity.7,8 The study
was approved by the human research ethics committee of
the University of California San Francisco (UCSF) Benioff
Children’s Hospital, and the Bambino Gesu Children’s
Hospital and Research Institute.
Results
Genetic findings
Sixteen patients had a family history of seizures in the
neonatal period (Fig. 1). Patient 8 had a family history of
seizures in the first months of life. Patient 15 had, in addi-
tion, a family history of idiopathic focal epilepsy in child-
hood. Three patients had KCNQ2 deletions and one patient
had a deletion in KCNQ3. The KCNQ2 deletion in patient 8
included the adjacent CHRNA4 gene, and this patient had a
typical BFNE phenotype, as reported by others.9 Two
patients had nonsense mutations, and two patients had fra-
meshift mutations predicted to lead to early truncation.
Seven patients had KCNQ2 missense mutations, including
three previously reported alleles. Patient 17 was without a
family history of epilepsy and was found to have a de novo
novel KCNQ2 mutation. Patient 12 had a novel missense
mutation in the pore region of KCNQ3. Both novel muta-
tions were predicted to be pathogenic with a high degree of
confidence.
Electroclinical features
Table 1 details the findings in the 19 patients diagnosed
with BFNE. Seizure onset was between 2 and 5 days (mean
2.9 days). Seizures were focal in onset in all patients con-
sisting of asymmetric tonic posturing accompanied in most
patients by apnea and desaturation, evolving in most
patients to unilateral or asynchronous bilateral clonic move-
ments (Fig. 2). Seizures lasted between 30 and 120 s,
occurred multiple times per day in all patients, and four
patients developed status epilepticus. Neuroimaging and
EEG background was normal in all patients. Focal interictal
EEG epileptiform abnormalities were recorded frequently
recorded (12 of 17 patients) over the central regions in 7
infants, over the centrotemporal or frontotemporal region in
4 infants, and from the right temporal and left occipital
regions in one other. The supplementary video shows a typi-
cal seizure recorded in patient 12 harboring a novel KCNQ3
mutation, before CBZ was administered.
Antiepileptic drug response
Twelve (63%) of 19 patients were trialed on multiple
AEDs prior to seizure cessation (Fig. 3). Fourteen patients
were trialed with intravenous loads of phenobarbital (PB)
and two responded; one was continued on oral PB and one
was switched to oral carbamazepine (CBZ) maintenance
therapy and remained seizure-free. The rest of these patients
did not respond, despite documented PB levels of ≥40 lg/
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mL. Additional treatments without response included intra-
venous pyridoxine in three infants, intravenous levetirac-
etam in three infants, high-dose intravenous
benzodiazepines (diazepam or midazolam) in four infants,
and oral benzodiazepines (clonazepam) in two infants. One
patient responded to intravenous thiopental. Patient 9
responded to a loading dose of intravenous phenytoin
(PHT), but seizures recurred at the first attempt to wean and
the patient subsequently responded to oral CBZ. After an ini-
tial response to levetiracetam (patient 1) and PB (patient 14),
seizures recurred and were not controlled with escalating
doses until seizure freedom was achieved with initiation of
CBZ at 3 months of age. Seventeen (89%) of 19 patients
were seizure-free within hours of administration of low-dose
oral CBZ (10 mg/kg/day) or oxcarbazepine (OXC), includ-
ing four in whomCBZwas used as the sole first-line therapy.
Earlier initiation of CBZ was associated with shorter dura-
tion of hospitalization (Fig. 4). Figure 4A excludes patients
1 and 14, who were hospitalized multiple times over the first
3 months for recurrent bouts of seizures and whose cumula-
tive hospitalizations lasted approximately 1 month each.
When CBZwas started within 3 days of seizure onset, hospi-
talization lasted under a week (Fig. 4B).
Treatment with CBZ was initiated based on the electro-
clinical presentation suggesting BFNE. No laboratory
abnormalities or side effects were reported during treatment
with CBZ. Three patients experienced seizure recurrence
with attempt to wean treatment in the first year of life:
patient 10 experienced recurrence with attempt to wean PB
at 2 months of age, and patients 8 and 11, following an
attempt to discontinue CBZ at 8 months. In all three of these
patients, reintroduction of the maintenance therapy
promptly led to seizure remission. The patient who
responded initially to OXC at 20 mg/kg/day (patient 17)
had seizure recurrence at 1.5 months of age, with a blood
level of 4 lg/mL, and responded to an increase in the dose
to 35 mg/kg/day. Doses were not otherwise weight adjusted
over the course of treatment, and all patients were seizure-
free after discontinuation of drugs between 12 and
18 months of life.
Mean follow-up was 7.8 years (6 months to 16 years).
All patients had normal development and none had evolu-
tion to encephalopathy or severe epilepsy (Table 1). Patient
15 developed epilepsy with centrotemporal spikes at
3 years of age, which did not respond to clobazam but did
respond to CBZ. One patient developed uncomplicated feb-
rile seizures.
Discussion
We report the first study to evaluate AED treatment in
neonates with BFNE. We aimed to review the response to
AEDs, including timing, impact on duration of hospitaliza-
tion in the neonatal intensive care unit (NICU), and
Figure 1.
Family trees in a cohort of with BFNE. Black: neonatal seizures. Red squares denote family members with febrile seizures. Striped: affected
family members of proband 15 developed idiopathic focal epilepsy in childhood as well as neonatal seizures. See Table 1 for details.
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long-term outcome. Our findings demonstrate that oral CBZ
is a safe and effective therapy for seizures in neonates with
BFNE, and moreover suggest that recognition of the electro-
clinical phenotype early in the clinical course can prompt
timely initiation of CBZ and avoid sedation and hypotonia
associated with loading doses of intravenous PB, which
delays establishment of oral feeding and consequently pro-
longs the NICU stay of these otherwise healthy babies.
The 19 patients reported here shared the hallmark fea-
tures of benign neonatal seizures: onset of seizures within
the first days of life in otherwise healthy neonates with nor-
mal interictal EEG findings and neuroimaging, who often
have a family history of seizures in the neonatal period. The
electroclinical phenotype was defined by prolonged video-
EEG monitoring and found to be stereotyped across our
cohort: clusters of focal seizures with alternating laterality,
characterized by initial asymmetric tonic posturing, often
with apnea and desaturation, followed by a clonic compo-
nent (Video S1). Electrographically, focal seizures arose
alternately from each hemisphere, out of a continuous EEG
background with or without epileptiform discharges but
without focal slowing or attenuation to suggest an underly-
ing lesion.
Similar to other studies of BFNE, the rate of mutation
detection in this cohort was approximately 85%.1,3,6 Our
cohort included one novel de novo missense mutation of
KCNQ2, a KCNQ3 deletion, and one novel mutation in the
KCNQ3 gene. The novel KCNQ2 missense mutation,
V567D, is in a region of the C-terminus near other residues
reported to be pathogenic. Although de novo mutations are
generally associated with KCNQ2 encephalopathy; in this
case, the allele appears to represent a founder mutation.
KCNQ2 deletion is a known cause of BFNE,10 but to our
knowledge KCNQ3 deletion has not previously been
reported as a cause of BFNE. We described a novel mis-
sense mutation in KCNQ3, W308S, in the channel pore pre-
dicted to be pathogenic with a high degree of confidence
and adjacent to one of the only 10 other sites for reported
missense mutations, W309R,11 which has been confirmed
in vitro to result in dramatically reduced potassium cur-
rents.12,13
It has been suggested that neonatal seizures should no
longer be regarded as a separate entity and that seizure semi-
ology should be approached in the same manner as with
older patients.14 Reviewing the video-EEG recordings of
our series of newborns with BFNE, we noted that the seizure
semiology has close similarities with seizures involving the
supplementary sensorimotor area (SSMA) as described in
older children and adults.15,16 Of interest, focal epilepsies
with SSMA and other frontal semiology appear to respond
well to CBZ.16–18 Attention to seizure semiology along with
review of the EEG background and the neurologic examina-
tion early in the clinical course and, in particular, prior to
the administration of large quantities of sedating
Figure 2.
Electroclinical phenotype of seizures in BFNE. (A) Asymmetric tonic posturing with apnea and desaturation during a benign neonatal sei-
zure (patient 12). Subsequently, the seizure evolved to asynchronous bilateral clonic movements. (B) Interictal EEG of the same patient,
showing focal epileptiform discharges in the bilateral central regions and at the vertex (arrows) in the setting of an otherwise normal back-
ground. (C) Electrographic seizure from this patient, showing onset of rhythmic sharpened delta over the left hemisphere.
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medications, was critical in raising early suspicion for
benign genetic epilepsy. In all patients, treatment was initi-
ated based on the electroclinical diagnosis, well before the
results of genetic testing were available. Early recognition
of BFNE is a prerequisite for implementation of tailored
therapy and appropriate prognostic counseling. CBZ could
be given as first-line therapy for two neonates (patients 6
and 11) who were siblings of previously diagnosed patients
in whom the genetic etiology had been confirmed and in
four others (patients 8, 12, 18, and 19) based on phenotype
alone.
The natural history of seizures in BFNE is unclear from
the literature, as these seizures have often been noted to dis-
appear after 6 months of age in many patients; details on
effective therapies and treatment duration are scarce. We
found oral CBZ to be effective in all treated patients, lead-
ing to seizure cessation within hours, regardless of at what
point in the clinical course it was initiated, even in the set-
ting of SE. Although benign in terms of developmental out-
come, seizures in BFNE were frequent at presentation and
associated with apnea and desaturation, leading to admis-
sion to the NICU. As a marker of its efficacy, we found that
the timing of treatment with CBZ was related directly to the
length of hospitalization. In the extreme, two infants were
repeatedly hospitalized over the first 3 months of life, with
approximately 1 month of hospitalization in each before
cessation of seizures after starting CBZ. In contrast, in four
cases in which CBZ was given as first-line therapy, the
length of hospitalization was <24 h. Patient 6 was not even
admitted and was treated as an outpatient.
There is little information to guide practitioners in the
duration of AED treatment in BFNE, although anecdotal
reports have suggested that seizures can recur if medications
are weaned prior to 9 months.19 Indeed, KCNQ2 mutation
Figure 3.
Treatment responses in BFNE. Antiepileptic therapies used across the cohort in the order in which they were administered. The last
therapy was associated with cessation of seizures. In case 9, phenytoin (PHT) led to seizure cessation, but seizures recurred with weaning
and carbamazepine (CBZ) was initiated with no further recurrence. LZP, lorazepam; PB, phenobarbital; LEV, levetiracetam; OXC, oxcar-
bazepine.
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not infrequently presents with benign epilepsy during
infancy outside of the neonatal period, arguing a window of
particular susceptibility that extends throughout the first
year of life.1 Our cohort is notable for the recurrence of sei-
zures in two patients at 8 months of age on attempt to dis-
continue therapy. In patients with follow-up beyond 2 years
of age, except for one patient who developed benign epi-
lepsy with centrotemporal spikes (BECTS), unprovoked
seizures did not recur after discontinuation of treatment
between 12 and 18 months, suggesting that this may be an
appropriate duration of therapy.
Although, CBZ, a sodium-channel blocker, has been used
in adults and children for >30 years with an excellent thera-
peutic and side effect profile, it is seldom used in newborns.
Its use in this population has been reported previously only
in two studies in term20 and preterm neonates.21 Consistent
with these reports, none of the 17 patients in our cohort trea-
ted with CBZ as neonates and infants experienced any gas-
trointestinal, hepatic, hematologic, renal, or dermatologic
side effects. We used a low dose of CBZ; however, since the
dose was not subsequently adjusted for weight, it is possible
that even lower doses may be effective.
Our study parallels the recent report of rapidly effective
treatment of the seizures in KCNQ2 encephalopathy to
CBZ.22 Although the two conditions result from mutation of
the same gene and the seizure semiology is similar, the dif-
ferential diagnosis can be made clinically based on the neu-
rologic examination and EEG background, both of which
are severely abnormal prior to onset of seizures in KCNQ2
encephalopathy.23 It has been speculated that co-localiza-
tion of voltage-gated potassium and sodium channels at
regions of the neuronal membrane critical for action poten-
tial generation and propagation24 may impart sensitivity to
sodium channel blockade. It is notable that one patient who
was treated with PHT did seem to respond, suggesting that
either of these sodium-channel blockers may be effective
treatment, although PHT may be less desirable for mainte-
nance drug during the first year of life. Although PHT is
known to potentially exacerbate SCN1A-related conditions,
relative success has been reported in treating early epilepsy
associated with mutations in SCN2A25,26 or SCN8A.27 In
addition, benign familial infantile epilepsy BFIE, a benign
autosomal-dominant epilepsy with a later age of presenta-
tion than BFNE and caused by mutation in the PRRT2 gene
in >70% of families,1 has also been shown to be sensitive to
low-dose CBZ.28 Indeed, sodium channel blockers are
emerging as old drugs with a new indication in treating early
onset genetic epilepsies. Epilepsies caused by PRRT2 and
KCNQ2 share in common focal seizures with a tonic com-
ponent,29 suggesting that seizure semiology is relevant for
treatment choice.
PB is the most commonly prescribed first-line agent for
neonatal seizures, regardless of etiology. However, intra-
venous loads of PB failed to stop seizures in the majority of
our patients with BFNE, despite serum levels of ≥40 during
bouts of recurring seizures. Indeed, only 2 of 13 patients
treated with PB had an apparent clinical response, and in
one CBZ was initiated simultaneously as maintenance
Figure 4.
(A) Length of hospitalization by time to CBZ. In patients treated with CBZ or OXC in the neonatal period, the length of hospitalization
was directly correlated with when CBZ or OXC was initiated, p < 0.01. (B) Administration of CBZ within 3 days of seizure onset was
associated with hospital stays of under 1 week, compared to longer hospitalization if CBZ was not administered or if initiated after
3 days, p < 0.01.
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therapy, leaving open the possibility that the response was
due to CBZ. Exacerbation of benign neonatal seizures with
PB followed by midazolam infusion has been reported pre-
viously.2 The particular combination of PB loading fol-
lowed by midazolam infusion was used in one of our
patients, whose seizures were ultimately aborted by
thiopental. It is unclear whether this clinical course reflects
exacerbation by the treatment protocol or the natural clinical
course. Because PB was used early in 13 of 19 of our
patients, it is unclear whether it could have led to more sei-
zures than anticipated due to poor efficacy alone. Notably,
CBZ was effective in babies who received a dose of PB as
first line and, moreover, initiation of CBZ within 3 days of
seizure onset was invariably associated with short duration
of hospitalization regardless of prior exposure to PB. Intra-
venous administration of PB in our cohort likely contributed
to prolonging the hospitalization due to sedation, hypotonia,
and difficulty with feedings.
Recently, it was demonstrated that up to 25% of neonates
with BFNE go on to have other forms of epilepsy later in
childhood.3 Only one patient in our cohort developed epi-
lepsy later in life. It is intriguing that seizure burden in the
neonatal period has been implicated in risk for epilepsy in
both human and animal studies.30–32 Although suggestive,
our cohort size is too small to draw conclusions regarding
whether prompt seizure control may have affected this risk.
The one patient in our cohort who developed epilepsy had a
KCNQ3 deletion and developed BECTS. BFNE due to
KCNQ2mutation and later development of BECTS has been
well described.3,33,34 BFNE due toKCNQ3 and later BECTS
has been noted in one patient previously,34 and one other has
been reported with benign infantile epilepsy who went on to
develop BECTS.35 Although CBZ was not used to treat this
patient’s seizures in the neonatal period, it was used success-
fully to treat his Rolandic seizures later in life, again sug-
gesting a connection between KCNQ2/3 mutations, seizures
with frontal lobe semiology, and response to CBZ.
Our study has the inherent limitations of a retrospective
study. Of particular concern would be that the apparent effi-
cacy of CBZ in our cohort was due to the self-limited nature
of the condition, seizures tending to abate over time in all
patients. We feel that this possibility is belied by the fact
that patients started on CBZ at any point in their course uni-
versally responded, including those started on CBZ as first
line. Another potential concern is that our results might be
derived from a bias, whereby less severely affected babies
were selected for early treatment with oral CBZ, whereas
more severely affected individuals were chosen for more
aggressive treatments. Although this possibility cannot be
ruled out, we note that all patients, regardless of treatments
trialed, were affected by recurrent clusters of seizures, and
in one patient CBZ was used as first line in the setting of sta-
tus epilepticus with rapid cessation of seizures. Whether
other AEDs that target the sodium channel would be equally
effective and safe in BFNE was not answered here.
Although OXC was effective and safe in one child, little can
be gleaned from a single patient, and at this point the authors
recommend treatment with CBZ as first line.
We have found CBZ to be a safe and rapidly effective
treatment for the seizures in BFNE, even when used to treat
SE. Prompt initiation of a trial of CBZ in neonates with
BFNE may reduce unnecessary exposures to other AEDs,
some of which (e.g., PB) have raised concerns for neurode-
velopmental effects,36 reduce the complications and costs
associated with protracted hospitalization in these otherwise
well neonates, and perhaps lower the risk of later epilepsy.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Video S1. Ictal video-EEG recorded in a neonate with a
KCNQ3 mutation (patient 12) during monitoring prior to
treatment. Administration of CBZ led to rapid cessation of
seizures.
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